Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of oral antidiabetic medications that act by reducing renal glucose reabsorption in the proximal convoluted tubule thus leading to increased glycosuria and lowering of blood glucose.1 This review intends to analyze SGLT-2 inhibitors with regards to their glycaemic efficacy glycaemic durability and other non-glycaemic effects (body weight blood pressure lipids) and adverse effect profile in individuals with diabetes.
Empagliflozin a sodium glucose co-transporter 2 inhibitor in the treatment of type 1 diabetes.
The ratio of this protein to p-actin enabled us to access the regional distribution of the sodium-phosphate co-transporter
Because dietary adaptation changes the velocity of phosphate transport, dietary-induced changes in reabsorption are likely to remove existing co-transporters or insert new co-transporters into the luminal membrane.
It may stimulate a rapid endocytosis of type II [Na.sup.+]/Pi co-transporters on the luminal membrane, thereby decreasing reabsorption.
Phosphorus utilization and renal sodium-phosphorus co-transporter gene expression could be affected by dietary true digestible calcium and phosphorus ratio in post-weaned pigs (Wang et al., 2008).
The effect of dietary nutrient density on growth performance, physiological parameters, and small intestinal type IIb sodium phosphate co-transporter expression in broilers.